Publications by authors named "P Bias"

Claim this Profile
E
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
Hartmut Link, G Illerhaus, U M Martens, A Salar, R Depenbusch, P Bias

Support Care Cancer· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Path Towards a Tailored Clinical Biosimilar Development.
Martin Schiestl, Gopinath Ranganna, Keith Watson, Byoungin Jung, Karsten Roth, Peter Bias

BioDrugs· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy.
Noah Federman, Monica D Dragomir, Zoryana Kizyma, Jelena Roganovic, Peter Bias

J Pediatr Hematol Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma.
Margarita B Belogurova, Zoryana P Kizyma, Miklós Garami, Mónika Csóka, Michael J Lamson, Peter Bias

Cancer Chemother Pharmacol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.
Constantin Volovat, Igor Bondarenko, Oleg Gladkov, Anton Buchner, Andreas Lammerich, Peter Bias

Support Care Cancer· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis